Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
Heather M Shaw, Marcia Hall Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, United Kingdom Abstract: Olaparib has shown promising anticancer activity as a single agent in the treatment and maintenance of recurrent ovarian cancer in early clinical trials, but it is far from stan...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-09-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/emerging-treatment-options-for-recurrent-ovarian-cancer-the-potential--a14251 |
| Summary: | Heather M Shaw, Marcia Hall Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, United Kingdom Abstract: Olaparib has shown promising anticancer activity as a single agent in the treatment and maintenance of recurrent ovarian cancer in early clinical trials, but it is far from standard therapy. This article outlines the problem of relapsed ovarian cancer and the mechanisms of poly(ADP-ribose) polymerase inhibitors and reviews the recent literature pertaining to olaparib in ovarian cancer. Keywords: anticancer, polymerase inhibitor |
|---|---|
| ISSN: | 1178-6930 |